Mitsui & Co., Ltd. ("Mitsui", Head office: Chiyoda-ku, Tokyo, President and CEO: Tatsuo Yasunaga), ITOCHU Corporation ("ITOCHU", Head office: Minato-ku, Tokyo, President and COO: Yoshihisa Suzuki) and Iyogin Capital Company Limited. ("IC company", Head office: Matsuyama-city, Ehime, Representative Director: Kenichi Oizumi) have invested approximately ¥520million to subscribe to a third-party allotment of new shares by Organ Technologies Inc. ("OT company", Head office: Minato-ku, Tokyo, President Yasuhiro Sugimura).

OT company with their corporate mission, "Contribution to the health of world people and improvement of the quality of life by Organ Regenerative Medicine and the wellness innovation of the model in the 21st century" have been proceeding operation energetically in a field of Regenerative Medicine, life health care and the medical health care. OT company, features in three technical categories, hair reproduction technology, dentistry reproduction technology and artificial skin technology. Especially for the hair regenerative medicine, OT company has advanced to the stage of the non-clinical test, and they push forward a plan for realization of the organ regenerative medicine from Japan steadily at first in the world. This investment is allotted to the funds for research and development of the OT company pipeline including the development for the offer of the hair regenerative medicine.

In the field of regenerative medicine, market expansion has been anticipated, and Mitsui judged that the partner ring with the company which has a high regenerative medicine technique is indispensable in promoting the action in the field of regenerative medicine and financed OT Company to precede toward industrialization in the domain in future. Mitsui supports growth of OT company through their wide industrial business assets and partner within Mitsui group and learns a latest regenerative medicine technology through co-operation and pushes forward an action in order to bring up the talented person who can build regenerative medicine business in the future.

This project is under the Business Innovation Project framework established by Mitsui in October, 2012. The Business Innovation Project framework, exempt from some of the investment and withdrawal criteria set within the company, is designed to support, from a long-term perspective, new business endeavors, such as the acquisition of R&D capabilities and participation in new business fields.

Profile of Organ Technologies Inc.

Precise manipulation for technical development of regenerative medicine

Laboratory for advanced researches